Skip to main content
. 2017 Feb 11;18(2):380. doi: 10.3390/ijms18020380

Figure 2.

Figure 2

Kaplan-Meier analysis of the subgroup of patients with a NLR <5 at baseline for (a) overall survival (OS) and (b) progression-free survival (PFS). There was no difference of median survival in the subgroup of patients with a NLR <5 at baseline and change of NLR to >5 vs. no change after eight weeks of Abiraterone therapy (log rank p = 0.21). There equally was no difference of median PFS for change of NLR to >5 vs. no change after eight weeks of Abiraterone therapy (log rank p = 0.21).